FierceBiotech Jan 21, 2026 Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
FierceBiotech Jan 21, 2026 FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma
FierceBiotech Jan 21, 2026 IO mulls more layoffs months after halving head count in wake of cancer vaccine setback
FierceBiotech Jan 21, 2026 Touching base: Beam CEO on gene editing biotech's 'big push' for in vivo delivery
FierceBiotech Jan 21, 2026 Nkarta’s CEO wore head-to-toe pink at JPM. Here’s why it matters more than ever
FierceBiotech Jan 20, 2026 Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years
FierceBiotech Jan 20, 2026 Boundless finally gives up on combo treatment of 2 unimpressive cancer drugs
FierceBiotech Jan 20, 2026 Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis
FierceBiotech Jan 20, 2026 Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark
FierceBiotech Jan 20, 2026 Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs
FierceBiotech Jan 20, 2026 GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair
FierceBiotech Jan 20, 2026 ARPA-H director eyes future beyond vaccines, ‘winning the biotech race’ against China
FierceBiotech Jan 19, 2026 FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions